Fujifilm Kyowa Kirin and Mylan EPD Launch Adalimumab Biosimilar in Japan

 Fujifilm Kyowa Kirin and Mylan EPD Launch Adalimumab Biosimilar in Japan

Fujifilm Kyowa Kirin and Mylan EPD Launch Adalimumab Biosimilar in Japan

Shots:

  • This is the first launch of a biosimilar to Humira in Japan. Mylan EPD will lead the commercialization of the biosimilar
  • The launch is a testament to the power of Viatris’ unique Global Healthcare Gateway which helps partners to further expand patient access to more affordable medicines across the globe
  • In 2018, Fujifilm Kyowa Kirin Biologics and Viatris collaborated for the commercialization of Hulio in the EU and Viatris has commercialized the product in 20+ countries across the region. In 2019, the companies expanded the partnership globally

Click here ­to­ read full press release/ article | Ref: Biosimilar Development | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post